Coya CEO Arun Swaminathan recently joined Ayesha Rashid and the XTalks Podcast to talk Treg therapies targeting neurodegenerative diseases. Tune into the episode below or wherever you get your podcasts to learn more about the pipeline: https://lnkd.in/evPZQCbx #CoyaTherapeutics
Coya Therapeutics, Inc.
生物技术研究
Houston，Texas 3,886 位关注者
Unleashing the power of Tregs to tackle neurodegenerative and autoimmune diseases.
关于我们
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. Coya’s mission is focused on the advancement of innovative therapeutic approaches to address the significant unmet medical needs of patients with serious neurodegenerative, autoimmune, and metabolic diseases. For more information about Coya, please visit www.coyatherapeutics.com.
- 网站
-
https://www.coyatherapeutics.com
Coya Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Houston，Texas
- 类型
- 私人持股
- 创立
- 2020
地点
-
主要
获取路线
5850 San Felipe St
Suite 500
US，Texas，Houston，77057
Coya Therapeutics, Inc.员工
动态
-
Coya Therapeutics recently supported runners in Run4Yitzi, an annual half marathon team running in support of Rabbi Yitzi and research for the devastating neurodegenerative disease #ALS. We're proud to support this team and continue to do the work to advance life-changing research to find better Treg therapies to treat it. Learn more at www.run4yitzi.com. #CoyaTherapeutics #EndALS #Research
-
-
Could diabetes drugs help protect the brain? GLP-1s are hot topics right now, and much research is still needed, but we feel there is a strong potential for them to be used in combination with other therapeutics in the fight against neurodegenerative diseases. In preclinical models, COYA 303, a combination of GLP-1 RA and COYA 301, has shown an additive/synergistic anti-inflammatory effect. We will share more updates! https://lnkd.in/eza9ZBxa https://lnkd.in/eS6vzurf https://lnkd.in/eabzCPE7 #GLP1s #Research #CoyaTherapeutics $COYA
-
-
Coya Therapeutics provided a corporate update today and announced our financial results for the year ended December 31, 2024. Read the release here: https://lnkd.in/eu3m9kRz $COYA #CoyaTherapeutics
-
Catch our CEO Arun Swaminathan on the latest episode of the Conversations Life Science Leaders Aren't Having podcast with host Jeff Harmon. He discusses his journey from scientist to CEO and the important work Coya Therapeutics is focused on: https://lnkd.in/e68wJXYV #CoyaTherapeutics #Neurodegenerative #Biotech
-
For difficult conditions like FTD, finding home care and other assistance can be daunting but caretakers don't have to go it alone. Partners like the The Association for Frontotemporal Degeneration (AFTD) are here to help identify options for care and support. Learn more about the options here: https://lnkd.in/e7Rqetad #EndFTD #HomeCare #Support
-
Very excited and hopeful for this partnership. If your life has been touched by someone with ALS, you know how awful the disease is and how limited the drug therapies currently are. This combination therapy approach could revolutionize treatment for ALS patients worldwide.
Our CEO Arun Swaminathan and Milan Kalawadia, CEO, North America of Dr. Reddy's Laboratories (RDY), are featured in Digital Journal discussing our partnership for the development and commercialization of COYA 302 for the treatment of ALS, why so many ALS drug trials are failing, and what makes COYA 302 different. Read the article here: https://lnkd.in/eqWkfuaR $COYA #ALS #EndALS #Neurodegenerative
-
Our CEO Arun Swaminathan and Milan Kalawadia, CEO, North America of Dr. Reddy's Laboratories (RDY), are featured in Digital Journal discussing our partnership for the development and commercialization of COYA 302 for the treatment of ALS, why so many ALS drug trials are failing, and what makes COYA 302 different. Read the article here: https://lnkd.in/eqWkfuaR $COYA #ALS #EndALS #Neurodegenerative
-
Coya Therapeutics is pioneering the research and developing COYA 302 to potentially enhance the function of regulatory T cells, also called Tregs. Tregs are a type of lymphocyte that modulate the body’s immune response and ameliorate inflammatory mechanisms and reactions. Learn more about how this research can change the way we treat #neurodegenerative diseases: https://lnkd.in/gR2jcFmD #als #ftd #neurodegenerative #drugdiscovery
-
-
Coya Therapeutics will participate in a KOL call hosted by BTIG to discuss the potential treatment of Alzheimer’s Disease using GLP-1 agonists and combinations on Feb. 27. Read more in our latest press release: https://lnkd.in/gJ5Nde3Q $COYA #CoyaTherapeutics #KOL #Event
-